TOVX

Theriva Biologics, Inc. (TOVX) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Theriva Biologics is a clinical-stage company that has transitioned its strategic focus to oncology, primarily developing VCN-01, an oncolytic adenovirus for pancreatic cancer and retinoblastoma. The company also maintains legacy gastrointestinal assets (SYN-004 and SYN-020) but is exploring out-licensing options for them. All share data has been retrospectively adjusted for a 1-for-25 reverse stock split effective August 26, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Impairment Charges: The company recorded significant non-cash impairment charges in Q3 2024 due to a sustained decline in stock price. This included a $1.3 million impairment of In-Process Research and Development (IPR&D) and a $1.5 million goodwill impairment. For the nine months ended September 30, 2024, total goodwill impairment was $5.6 million.
• Expense Fluctuations: General and Administrative (G&A) expenses increased to $2.3 million in Q3 2024 from $0.2 million in Q3 2023. This variance is largely driven by a $0.5 million increase in contingent consideration fair value in 2024 versus a $1.5 million decrease in 2023.
• R&D Expenses: R&D expenses decreased to $2.7 million in Q3 2024 from $4.0 million in Q3 2023, primarily due to lower clinical trial costs for the VIRAGE Phase 2 trial and completion of the SYN-020 Phase 1a trial.
• Capital Structure: The company completed a public offering in September 2024, raising approximately $2.5 million gross proceeds. Additionally, all outstanding Series C and Series D Convertible Preferred Stock was converted to common stock during the quarter.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. As of September 30, 2024, cash was $16.4 million. Management believes this is sufficient to fund operations into the third quarter of 2025, but not for the full 12 months following the filing date. Additional equity or debt financing is required to continue development.
• Clinical Progress:
  • VCN-01 (Pancreatic Cancer): Achieved target enrollment of 92 patients in the Phase 2 VIRAGE trial. No safety concerns were raised by the Independent Data Monitoring Committee (IDMC).
  • VCN-01 (Retinoblastoma): Received Orphan Drug Designation from the European Commission and Rare Pediatric Drug Designation from the FDA. Positive topline data from a Phase 1 intravitreal trial was announced.
  • SYN-004: Positive DSMC review for Cohort 2 of the Phase 1b/2a trial in allogeneic HCT recipients. Enrollment for Cohort 3 is pending additional funding.
• Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding review controls for complex accounting and IT general controls. Remediation efforts are ongoing.
• Listing Status: The company faces risks regarding continued listing on NYSE American due to minimum stockholders' equity and share price requirements.

Investor Verification Checklist

• Cash Runway: Verify the specific burn rate and confirm the timeline for the next capital raise, given the "substantial doubt" going concern warning.
• Impairment Drivers: Review the specific assumptions used in the goodwill and IPR&D impairment tests (discount rates, probability of success) to understand if the decline in valuation reflects operational issues or market volatility.
• Internal Control Remediation: Monitor the progress of remediation for the identified material weaknesses in financial reporting and IT controls.
• VCN-01 Data Readout: Track the timeline for the top-line data release from the Phase 2 VIRAGE trial, which is critical for future valuation and funding.
• SYN-004 Strategy: Confirm if the company secures a partner or grant to fund Cohort 3 of the SYN-004 trial, as internal funding is currently prioritized for VCN-01.